Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Summary

The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.

Timeline

Start

2018-07-11

Primary completion

2018-07-11

Completion

2018-07-11

Outcome

Outcome not reported

Stopped: “Study was stopped to pursue a new treatment plan with a new study.”

Drugs

Indications